STOCK TITAN

Eliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company, announced that Bob Azelby, its President and CEO, will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 3:00 PM ET. The presentation will focus on developing novel therapies for neuronal excitability disorders, including chronic pain, psychiatry, and epilepsy. A live webcast will be available on their website, with a replay accessible for 30 days post-conference. Eliem aims to enhance patient quality of life through innovative therapeutic approaches.

Positive
  • None.
Negative
  • None.

SEATTLE and CAMBRIDGE, United Kingdom, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today announced that Bob Azelby, Eliem’s president and chief executive officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference being held virtually on Friday, February 18, 2022 at 3:00 PM ET.

A live webcast will be available on the Investors section of the Eliem Therapeutics website at https://www.eliemtx.com. An archived replay will remain available on Eliem’s website for at least 30 days after the conference.

About Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. Eliem channels its experience, energy, and passion for improving patients’ quality of life to fuel our efforts to develop life-changing novel therapies. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.
https://eliemtx.com/

Investors
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
339-970-2843

Media
Marites Coulter
Verge Scientific
Mcoulter@vergescientific.com
415.819.2214


FAQ

What is the presentation date for Eliem Therapeutics at the SVB Leerink Global Healthcare Conference?

Eliem Therapeutics will present on February 18, 2022, at 3:00 PM ET.

Who is presenting for Eliem Therapeutics at the conference?

Bob Azelby, the President and CEO, will present at the conference.

How can I watch the Eliem Therapeutics presentation?

The presentation will be available via live webcast on Eliem's website.

What are the main focuses of Eliem Therapeutics?

Eliem focuses on developing therapies for neuronal excitability disorders such as chronic pain, psychiatry, and epilepsy.

Is there a replay of the Eliem Therapeutics presentation available?

Yes, an archived replay will be accessible on Eliem’s website for at least 30 days after the conference.

Eliem Therapeutics, Inc

NASDAQ:ELYM

ELYM Rankings

ELYM Latest News

ELYM Stock Data

342.68M
67.06M
10.38%
77.67%
1.72%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WILMINGTON